株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨髄異形成症候群:パイプライン分析

Myelodysplastic Syndrome - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 229721
出版日 ページ情報 英文 1542 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.10円で換算しております。
骨髄異形成症候群:パイプライン分析 Myelodysplastic Syndrome - Pipeline Review, H2 2019
出版日: 2019年12月16日 ページ情報: 英文 1542 Pages
概要

骨髄異形成症候群(MDS)とは、骨髄およびそこで生成される血液細胞に発生する障害の一つです。その初期段階では、徴候・症状が現れることはほとんどありません。女症状として、倦怠感や息切れ、貧血に伴う顔面の異常な蒼白、容易かつ異常なあざ・出血、感染症の頻繁な発症などが挙げられます。

当レポートでは、世界各国での骨髄異形成症候群治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

骨髄異形成症候群の概要

治療薬の開発

  • 骨髄異形成症候群向けパイプライン製品:概要
  • 骨髄異形成症候群向けパイプライン製品:比較分析

各企業で開発中の骨髄異形成症候群治療薬

大学/研究機関で研究中の骨髄異形成症候群治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

骨髄異形成症候群治療薬:開発中の製品の一覧(企業別)

骨髄異形成症候群治療薬:研究中の製品の一覧(大学/研究機関別)

骨髄異形成症候群治療薬の開発に従事している企業

骨髄異形成症候群:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

骨髄異形成症候群治療薬:パイプライン製品の最新動向

骨髄異形成症候群治療薬:開発が休止状態の製品

骨髄異形成症候群治療薬:開発が中止された製品

骨髄異形成症候群関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Myelodysplastic Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..12), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..7), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2019
  • Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Altor Bioscience LLC, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Amphivena Therapeutics Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Angiocrine Bioscience Inc, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Apogenix AG, H2 2019
  • Myelodysplastic Syndrome - Pipeline by Aprea Therapeutics AB, H2 2019
  • Myelodysplastic Syndrome - Pipeline by AptaBio Therapeutics Inc, H2 2019

List of Figures

  • Number of Products under Development for Myelodysplastic Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11701IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 84, 63, 2, 8, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 9, 4 and 3 molecules, respectively.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Myelodysplastic Syndrome - Overview
  • Myelodysplastic Syndrome - Therapeutics Development
  • Myelodysplastic Syndrome - Therapeutics Assessment
  • Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
  • Myelodysplastic Syndrome - Drug Profiles
  • Myelodysplastic Syndrome - Dormant Projects
  • Myelodysplastic Syndrome - Discontinued Products
  • Myelodysplastic Syndrome - Product Development Milestones
  • Appendix